Pneumococcal disease: cases caused by strains covered by Prevenar 13 vaccine
Updated 28 March 2024
Applies to England
© Crown copyright 2024
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/pneumococcal-disease-cases-caused-by-strains-covered-by-prevenar-13-vaccine/pneumococcal-disease-cases-caused-by-strains-covered-by-prevenar-13-vaccine
The number of invasive pneumococcal disease (IPD) cases due to any of the 13 serotypes in Prevenar13TM was the lowest during the 2020 to 2021 epidemiological year due to the COVID-19 pandemic and its associated restrictions.
From 2021 to 2022, the number of cases remained lower than previous years in persons aged 5 years or over, but in children under 5 years, case numbers were similar to those in the years prior to the COVID-19 pandemic.
During 2022 to 2023, the cumulative number of cases was higher than in any year since the 2017 to 2018 epidemiological year for all age groups. As of week 9 of 2023 to 2024, case numbers are consistent with epidemiological years prior to 2022 to 2023, across all age groups.
The 2006 to 2007 epidemiological year corresponds to the year in which Prevenar 7TM was implemented in the childhood immunisation schedule (September 2006). The 2009 to 2010 and 2013 to 2014 epidemiological years corresponds to the year in which Prevenar 13TM was implemented (April 2010) and 4 years following, respectively.
Figure 1
Cumulative weekly number of reports of Invasive Pneumococcal Disease due to any serotype in Prevenar13TM: Children aged less than 2 years in England by epidemiological year July to June (selected years and 2017 to 2018 to date)
Figure 2
Cumulative weekly number of reports of Invasive Pneumococcal Disease due to any serotype in Prevenar13TM: Children aged 2 to 4 years in England by epidemiological year July-June (selected years and 2017 to 2018 to date)
Figure 3
Cumulative weekly number of reports of Invasive Pneumococcal Disease due to any of the serotypes in Prevenar13TM: Persons aged 5 to 64 years in England by epidemiological year July to June (selected years and 2017 to 2018 to date)
Figure 4
Cumulative weekly number of reports of Invasive Pneumococcal Disease due to any of the serotypes in Prevenar13TM: Persons aged 65 and over England by epidemiological year July to June (selected years and 2017 to 2018 to date) Source: Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency (UKHSA) (formerly Public Health England).
The graphs are based on week of isolation so numbers for the most recent weeks may not be complete. Number of reported cases shown in the graphs are not adjusted to account for any change that may have occurred over time and between age groups in the proportion of all IPD cases that are serotyped.
The 7-valent pneumococcal conjugate vaccine was introduced into the childhood immunisation schedule on 4 September 2006, which corresponds with week 36 in the graphs.
The 13-valent pneumococcal conjugate vaccine was introduced into the childhood immunisation schedule on 1 April 2010, which corresponds with week 13 in the graphs. The vaccine schedule for this vaccine changed for infants born on or after January 2020 (with doses given at 12 weeks and 1 year of age (1+1) instead of 8 weeks, 16 weeks and 1 year of age (2+1)), which corresponds with week 0 above.